# SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

> **NCT02580305** · PHASE2 · COMPLETED · sponsor: **Suven Life Sciences Limited** · enrollment: 564 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** SUVN-502
- **DRUG:** Placebo
- **DRUG:** Donepezil
- **DRUG:** Memantine

## Key facts

- **NCT ID:** NCT02580305
- **Lead sponsor:** Suven Life Sciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2019-11-05
- **Final completion:** 2019-11-07
- **Target enrollment:** 564 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580305, "SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02580305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*